Phase 3 Readout

HALO: Phase 3 Topline: Open-Label, Multiple-Dose, 52-Week Study + 24-Month Long-Term Safety Extension to Evaluate the Safet

Name: Phase 3 Topline: Open-Label, Multiple-Dose, 52-Week Study + 24-Month Long-Term Safety Extension to Evaluate the Safet
Start: 2030-03-01
End: 2030-03-01

March 1, 2030. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: March 1, 2030
Company: HALOZYME THERAPEUTICS, INC. (HALO)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: Open-Label, Multiple-Dose, 52-Week Study + 24-Month Long-Term Safety Extension to Evaluate the Safet

March 1, 2030

HALO overview →

Company: HALOZYME THERAPEUTICS, INC. (HALO)
Indication: Hypogonadism, Male